Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp lowered its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 2.1% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 171,313 shares of the biopharmaceutical company’s stock after selling 3,704 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.29% of Vanda Pharmaceuticals worth $786,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of VNDA. American Century Companies Inc. raised its stake in Vanda Pharmaceuticals by 2.1% during the 4th quarter. American Century Companies Inc. now owns 300,276 shares of the biopharmaceutical company’s stock valued at $1,438,000 after purchasing an additional 6,079 shares during the period. JPMorgan Chase & Co. grew its holdings in shares of Vanda Pharmaceuticals by 108.9% during the fourth quarter. JPMorgan Chase & Co. now owns 335,741 shares of the biopharmaceutical company’s stock valued at $1,608,000 after buying an additional 175,019 shares in the last quarter. Norges Bank acquired a new position in Vanda Pharmaceuticals during the fourth quarter valued at $551,000. Brandywine Global Investment Management LLC lifted its stake in Vanda Pharmaceuticals by 13.9% in the 4th quarter. Brandywine Global Investment Management LLC now owns 39,390 shares of the biopharmaceutical company’s stock worth $189,000 after acquiring an additional 4,820 shares in the last quarter. Finally, Wellington Management Group LLP boosted its position in Vanda Pharmaceuticals by 12.7% during the 4th quarter. Wellington Management Group LLP now owns 348,846 shares of the biopharmaceutical company’s stock worth $1,671,000 after acquiring an additional 39,195 shares during the period. 88.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a report on Wednesday, May 7th. Wall Street Zen lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Saturday. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 14th.

Insiders Place Their Bets

In other Vanda Pharmaceuticals news, Director Stephen Ray Mitchell sold 7,000 shares of the stock in a transaction on Friday, June 13th. The shares were sold at an average price of $4.59, for a total transaction of $32,130.00. Following the transaction, the director directly owned 97,082 shares of the company’s stock, valued at $445,606.38. This represents a 6.73% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Mihael Hristos Polymeropoulos acquired 10,000 shares of the stock in a transaction dated Wednesday, May 21st. The shares were bought at an average cost of $4.40 per share, for a total transaction of $44,000.00. Following the acquisition, the chief executive officer owned 2,325,731 shares in the company, valued at $10,233,216.40. The trade was a 0.43% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 10.00% of the company’s stock.

Vanda Pharmaceuticals Price Performance

Shares of VNDA stock opened at $4.19 on Friday. Vanda Pharmaceuticals Inc. has a fifty-two week low of $3.81 and a fifty-two week high of $5.56. The stock’s 50-day moving average is $4.64 and its two-hundred day moving average is $4.54. The firm has a market cap of $246.93 million, a P/E ratio of -3.71 and a beta of 0.68.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.12). The firm had revenue of $52.59 million during the quarter, compared to analyst estimates of $54.77 million. Vanda Pharmaceuticals had a negative return on equity of 12.89% and a negative net margin of 32.90%. As a group, research analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.